title: Overview of clinical studies in hemodiafiltration: what do we need now ?
abstract: Despite several technical advances in dialysis treatment modalities and a better patient care management including correction of anemia, suppression of secondary hyperparathyroidism, lipid and oxidative stress profiles improvement, the morbidity and the mortality of dialysis patients still remain still elevated. Recent prospective interventional trials in hemodialysis (HEMO study and 4D study) were not very conclusive in showing any significant improvement in dialysis patient outcomes. High-efficiency convective therapies, such as online hemodiafiltration (HDF), are claimed to be superior to conventional diffusive hemodialysis (HD) in improving the dialysis efficacy and in reducing intradialytic morbidity and all-cause and cardiovascular mortality in dialysis patients. The aim of this report was, first, to review the evidence-based facts tending to prove the superiority of HDF vs. HD in terms of efficacy and tolerance, and, second, to analyze the needs to prove the clinical superiority of HDF in terms of reducing morbidity and all-cause mortality of dialysis patients. A systematic review of studies comparing HDF and HD has been performed in the microbiological safety of online production, the solute removal capacity of small and medium-size uremic toxins, and its implication in the reduction of the bioactive dialysis system vs. patient interaction. Major planned randomized international studies comparing HDF and HD in terms of morbidity and mortality have been reviewed. To conclude, it is thought that these long-term prospective randomized trials will clarify on a scientific evidence-based level the putative beneficial role of high-efficiency HDF modalities on dialysis patient outcomes.
authors.affiliation: Nephrology, Dialysis and Intensive Care, University Hospital, Montpellier-F, France. b-canaud@chu-montpellier.fr
authors.forename: Bernard
authors.initials: B
authors.lastname: Canaud
authors.forename: Marion
authors.initials: M
authors.lastname: Morena
authors.forename: Hélène
authors.initials: H
authors.lastname: Leray-Moragues
authors.forename: Lofti
authors.initials: L
authors.lastname: Chalabi
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Cristol
mesh_terms: D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control; D002986:Clinical Trials as Topic; D017583:Hemodiafiltration / Q000009:adverse effects / Q000379:methods* / Q000592:standards; D006801:Humans; D006435:Renal Dialysis / Q000009:adverse effects / Q000592:standards; D016896:Treatment Outcome